EIT Health’s Venture Centre of Excellence Names ProductLife Group as Privileged Partner for Regulatory & ComplianceLearn More
ProductLife Group Announces Acquisition of Zwiers Regulatory Consultancy and Coverage Expansion to the NetherlandsLearn More
The Acquisition of Pharma IT Will Enable PLG to Strengthen its Foothold in Northern Europe and Offer New Services in the Context of Life Sciences DigitilisationLearn More
Pharma IT Solutions
Quality & Compliance
Safety & Vigilance
28 february 2022
Since mid-2018 when EU regulators were first alerted to the presence of nitrosamine impurities in blood pressure medicines, there has been a pressing need to remove the risk to patients. Nitrosamines are classified as probable human carcinogens based on animal studies.
As such, the European Medicines Agency (EMA) completed a review in June 2020 under Article 5(3) of Regulation (EC) No 726/2004 to advise marketing authorization holders (MAHs) on risk measures to address nitrosamine impurities, including N-nitrosodimethylamine. The FDA and other health authorities have taken a similar approach. The Committee for Human Medicinal Products asked MAHs to review all chemical and biological human medicines for the possible presence of nitrosamines and to test products at risk.
Companies are required to have appropriate control strategies to prevent or limit the presence of these impurities and, where necessary, to improve their manufacturing processes. A three-step approach was proposed by the authority.
Step 1 Risk Evaluation – The outcome of a risk evaluation to identify active substances and finished products at risk of N-nitrosamine contamination was required to be reported by 31 March 2021 for chemical medicines and 1 July 2021 for biological medicines.
Step 2 Confirmatory Testing – If a risk was identified in Step 1, confirmatory testing on the products should be performed and the confirmed presence of nitrosamines above the acceptable levels reported as soon as possible.
Step 3 Update of Marketing Authorization – When testing performed in Step 2 confirms the presence of nitrosamines, the MAH must control the limits in the API, and/or make any necessary changes to the manufacturing process of the finished product (including packaging), to remove the nitrosamines risk. This is done by requesting a variation to the marketing authorization. The MAH should complete the confirmatory testing and submit their variation applications by 26 September 2022 for chemical medicines and 1 July 2023 for biological medicines. To meet these deadlines, MAHs must perform the step 2 confirmatory testing activities well in advance.
ProductLife Group can help MAHs ensure they conform with the requirements in several ways:
Step 2 Confirmatory Testing
Our regulatory teams have expertise in compilation, format, content, evaluation and review of the Step 2 report, including:
We also have expertise in:
Step 3 Update of Marketing Authorization – Variation
Expertise in compilation, format, content, evaluation, and review of the Step 3 report, including:
Step 3 Update of Marketing Authorization – Referral
If the N-nitrosamine presence is confirmed to be intrinsic to the API (e.g. a structural feature or a metabolic formation) and/or if additional root causes for the presence of nitrosamines are reported and require further extensive assessment, then the regulatory authority may initiate a referral procedure. Again, these are assessments that ProductLife Group can assist with.
Contact us to find out how we can help you manage all the complexities surrounding nitrosamine contamination.
Go to our Events to register
Go to our News to get insights